As the SIRT1 small molecule activator with oral activity, SRT3025 increases the expression of hepatic LDL receptors and accumulation of proprotein convertase subtilisin/kexin type 9 (Pcsk9), reduces plasma cholesterol level, inhibits inflammatory response and atherosclerosis 183. This evidence concerns the gene PCSK9 and atherosclerosis.